Saltar al contenido
Merck

Upregulation of LGMNP1 confers radiotherapy resistance in glioblastoma.

Oncology reports (2019-04-20)
Hao Xu, Binghong Chen, Jin Xing, Zilong Wei, Chaobo Liu, Yongming Qiu, Yingying Lin, Li Ren
RESUMEN

Glioblastoma is a lethal brain tumor type, which is frequently resistant to radiotherapy. The aim of the present study was to explore the function of legumain pseudogene 1 (LGMNP1) on radioresistance in glioblastoma. Reverse transcription‑quantitative PCR was used to detect the relative expression of LGMNP1 in glioma cell lines after radiotherapy. Ectopic expression of LGMNP1 was achieved by transfection of a lentiviral vector. A clonogenic assay was used to determine the colony formation ability following radiotherapy. A comet assay, flow cytometry and western blot analysis were applied to detect DNA damage, the apoptotic rate, and levels of apoptotic proteins, respectively. The results revealed that LGMNP1 was significantly upregulated in glioma cells after radiation. Glioma cells stably overexpressing LGMNP1 were successfully established. Overexpression of LGMNP1 in glioma cells reduced DNA damage processes and the percentage of apoptotic cells after radiotherapy. In addition, overexpression of LGMNP1 in glioblastoma multiforme cells decreased apoptotic protein expression after radiotherapy. The present results indicated that upregulation of LGMNP1 conferred radiotherapy resistance by increasing the ability of DNA damage protection and reducing the apoptotic population in glioma cells.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Monoclonal Anti-Rabbit IgG, Native antibody produced in mouse, clone RabT-50, purified from hybridoma cell culture
Sigma-Aldrich
Anti-Mouse IgG3 (heavy chain specific) antibody produced in goat, affinity isolated antibody, lyophilized powder